

and warranties in the Credit Agreement.

As previously indicated in the Company's Current Report on Form 8-K filed on March 5, 2008, on March 5, 2008 the Company borrowed \$120 million under the Credit Agreement. The Company used these funds to repay the Company's 2 1/2% contingent convertible subordinated notes due 2008 upon conversion or maturity. As a result of the conversions, the Company issued 768,221 shares of the Company's common stock.

Statements in this Current Report on Form 8-K may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflect the Company's judgment as of the date of this report. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results, including, without limitation, the Company's inability to cure any defaults under the Credit Agreement or the Indentures, the Company's ability to repay indebtedness under the Credit Agreement, market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and information contained in subsequent filings with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: April 30, 2008

By: /s/ John B. Henneman, III

John B. Henneman, III
Executive Vice President, Chief Administrative
Officer and Acting Chief Financial Officer